QTTB Q32 Bio Inc.
USHealthcareAs of 2026-07-10 16:00
Why QTTB matters now
Q32 Bio Inc. (QTTB) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.21 with -10.96% on the session and $143.2M in market capitalization; recent performance reads 1-month +96.05% and YTD +258.43%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-7.6M, and EPS of $-0.54. Investors can compare that operating picture with valuation signals such as P/E 2.43 and FCF yield -18.0%.
The latest indexable market news headline is "Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.50; recent insider activity includes Lundberg Sven Ante filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
2.43
PEG
0.01
P/B
3.62
P/S
2.83
EV/EBITDA
5.19
DCF Value
$3.20
FCF Yield
-18.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.3%
Operating Margin
39.8%
Net Margin
61.9%
ROE
230.7%
ROA
52.2%
ROIC
35.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-7.6M | $-0.54 |
| Q4 2025 | $53.7M | $57.7M | $4.58 |
| FY 2025 | $53.7M | $29.8M | $2.42 |
| Q3 2025 | $0.00 | $-7.4M | $-0.60 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.50
Target (Median)
$13.50
Target Range
$13.00 - $14.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.23
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.